14 September 2020 in European Journal of Neurology
Background: Coronavirus disease 2019 (COVID‐19) typically presents with respiratory illness ranging in severity. Neurological complications of the disease remain largely unknown. Herein, we discuss the case of a woman diagnosed with COVID‐19 meningitis following two positive cerebrospinal fluid (CSF) RT‐PCR assays, and highlight the importance of recognizing the neurological manifestations of the disease.Case report: The patient was a 49‐year‐old woman with a history of hypertension who presented with non‐specific symptoms (fever, headache, malaise, nausea/vomiting). Chest computed tomography (CT) revealed a lack of pulmonary involvement and oropharyngeal/nasopharyngeal RT‐PCR was negative for COVID‐19. A lumbar puncture was performed on the third day of admission and the CSF analysis elucidated a viral pattern, but the CSF bacterial culture and RT‐PCR assay for herpes simplex virus were both negative. Surprisingly, the CSF RT‐PCR for COVID‐19 was positive. The diagnosis of COVID‐19 meningitis was made and the patient was treated solely with Kaletra®, with a second CSF analysis confirming our unique finding 1 week later. The patient's clinical characteristics improved progressively, and she was discharged in excellent general condition after 21 days.Conclusion: In contrast to what was originally believed, the SARS‐CoV‐2 can cause meningitis in isolation, perhaps by crossing the blood‐brain barrier. Hence, it seems essential that physicians maintain a high index of suspicion for neurological involvement among COVID‐19 patients, with early CSF analysis and brain imaging sometimes being indicated.
15 September 2022 in Seizure: European Journal of Epilepsy
31 October 2022 in Journal of Cosmetic Dermatology
Post‐acne scarring is the most common permanent consequence of acne vulgaris. Subcision is an intervention in which a needle or blunt cannula is inserted under the scar and moved back and forth to cut fibrotic strands and form new connective tissue, thereby elevating the atrophic scars. In this study, we reviewed the efficacy and adverse effects of different subcision techniques alone or in combination with other modalities to manage acne scars. The terms (subcision), (subcision AND acne scar), and (subcision AND scar) were searched in PubMed and Google Scholar. We included all available reports on clinical trials written in English and published before June 2022. A total of 16 relevant articles were identified after reviewing the abstracts and full texts. Four articles compared blunt cannula‐based subcision as a modified technique with needle‐based subcision as a conventional method, while the others investigated the combination of subcision with other modalities. According to our findings, subcision is a safe and effective method for treating atrophic acne scars. Needle‐based subcision and cannula‐based subcision offer comparable efficacy, with the latter causing fewer side effects and inducing greater patient satisfaction. Combining subcision with the application of autologous tissues (platelet gel) or artificial materials (hyaluronic acid gels and threads) as fillers can improve outcomes and prevent the re‐depressing of scars, as can its combination with frequent suctioning. Combinations with microneedling or fractionated microneedle radiofrequency have also been safe and effective. We conclude that modifications of the subcision procedure lessen its side effects, and combination therapies improve its efficacy.
28 November 2022 in Journal of Cosmetic Dermatology
Introduction: Skin pores are enlarged openings of the pilosebaceous follicles that can be affected by age, gender, genetics, exposure to UV light, ethnicity, and sebum secretion. Many treatment modalities reduce facial pores’ count and area, including oral and topical medications as well as different wavelengths of lasers. Finding a safe and cost‐effective treatment protocol is necessary since facial pores are one of the main reasons for cosmetic complaints.Aim: This review compares available treatment options for reducing facial pores’ number and area according to the published clinical trials.Methods: A search on PubMed and Google Scholar was performed. Nineteen published clinical trials regarding treatment options for facial pores were included and reviewed based on the authors’ clinical experience.Results: A total number of 591 cases (83.7% female) aged 18–80 years were included. Three assessment methods including digital imaging, physician assessment, and patient’ satisfaction were used in the studies to evaluate the therapeutic efficacy of each modality. Furthermore, combining different modalities increased the efficacy of reducing pores’ size and number. Mild, reversible burning and erythema were common side effects.Conclusion: Multiple sessions and combination therapies improve facial pores’ area and number. In young patients, the focus should be on controlling sebum production, while in older patients, the focus should be on rejuvenation in addition to the control of sebum production.
13 October 2021 in Clinical Case Reports
MDMohammad Shahidi Dadras
+1
COVID‐19 should be considered as a new triggering factor for autoimmune disorders like DM‐lupus overlap syndrome. We recommend that patients presenting with dermatomyositis during this pandemic be screened for COVID‐19.
31 March 2023 in Journal of Cosmetic Dermatology
Introduction: Palmar hyperhidrosis or excessive palmar sweating can reduce one's quality of life as it is associated with significant physical and occupational disabilities. We compared the gel and nanoemulgel of oxybutynin in treating these patients.Materials and Methods: This pilot study was performed as a double‐blind controlled randomized clinical trial at Shahid Faghihi Hospital, Shiraz, Iran. In two randomly allocated groups of 15, patients diagnosed with primary palmar hyperhidrosis by an attending dermatologist applied half a fingertip (roughly 0.25 g) of 1% oxybutynin topical gel or 1% oxybutynin nanoemulgel to both palms every 12 h for one month. The Hyperhidrosis Disease Severity Scale (HDSS), Visual Analog Scale (VAS), and Dermatology Life Quality Index (DLQI) were used to assess the patients at the beginning and end of the study. Statistical analysis was performed using SPSS version 25.Results: The groups were similar in terms of age (p = 0.800), sex (p = 0.096), and baseline HDSS, VAS, and DLQI scores. The mean HDSS scores decreased significantly (p = 0.001) over time in patients receiving the gel (3.00 ± 1.00 vs. 2.33 ± 0.61) or nanoemulgel (2.92 ± 0.82 vs. 2.14 ± 0.53), without a significant difference between the groups. The same was true for the VAS and DLQI scores. Three patients in each group experienced transient, self‐limited anticholinergic side effects (p = 0.983).Conclusion: Oxybutynin gel and nanoemulgel offer equal safety and similar efficacy in reducing the disease severity and increasing the quality of life of patients with palmar hyperhidrosis.